Wall Street brokerages expect Sophiris Bio Inc (NASDAQ:SPHS) to announce earnings per share of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Sophiris Bio’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.17). Sophiris Bio posted earnings per share of ($0.11) during the same quarter last year, which would suggest a negative year over year growth rate of 27.3%. The firm is scheduled to report its next earnings results on Thursday, November 8th.
On average, analysts expect that Sophiris Bio will report full year earnings of ($0.60) per share for the current financial year, with EPS estimates ranging from ($0.69) to ($0.48). For the next year, analysts expect that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.54). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last released its quarterly earnings data on Tuesday, August 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.05).
A number of equities analysts have weighed in on the company. ValuEngine lowered Sophiris Bio from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Maxim Group reiterated a “buy” rating and set a $8.00 price objective on shares of Sophiris Bio in a research note on Wednesday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $4.30 price objective (down previously from $6.00) on shares of Sophiris Bio in a research note on Monday, June 25th.
In related news, insider Randall E. Woods acquired 10,000 shares of Sophiris Bio stock in a transaction on Wednesday, September 19th. The stock was acquired at an average price of $2.63 per share, for a total transaction of $26,300.00. Following the purchase, the insider now owns 10,000 shares of the company’s stock, valued at approximately $26,300. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.
An institutional investor recently raised its position in Sophiris Bio stock. Northern Trust Corp lifted its holdings in Sophiris Bio Inc (NASDAQ:SPHS) by 293.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,600 shares of the biopharmaceutical company’s stock after purchasing an additional 60,092 shares during the period. Northern Trust Corp owned about 0.27% of Sophiris Bio worth $226,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.62% of the company’s stock.
Shares of NASDAQ SPHS traded down $0.02 during trading on Monday, reaching $2.45. 450,000 shares of the company traded hands, compared to its average volume of 373,113. The firm has a market capitalization of $84.01 million, a P/E ratio of -6.13 and a beta of 1.40. Sophiris Bio has a 12-month low of $1.80 and a 12-month high of $4.05. The company has a debt-to-equity ratio of -3.97, a quick ratio of 3.57 and a current ratio of 3.57.
Sophiris Bio Company Profile
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Featured Story: Market Capitalization and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.